Amonafide: An Active Agent in the Treatment of Previously Untreated Advanced Breast Cancer—a Cancer and Leukemia group B Study (Calgb 8642)

Clinical Cancer Research

Volumn 1, Issue 7, 1995, Pages 699-704

  Costanza, Mary E ^a   Berry, Donald ^b   Henderson, I Craig ^c   Ratain, Mark J ^d   Wu, Katherine ^b   Shapiro, Charles ^e   Duggan, David ^f   Kalra, Jagmohan ^g   Berkowitz, Irving ^h   Lyss, Alan P ⁱ  

^a Central Massachusetts Oncology Group ^*  (United States)

^b Cancer and Leukemia Group B Statistical Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^g LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^h UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

ⁱ BARNES JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMONAFIDE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LEUKOPENIA; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; IMIDES; ISOQUINOLINES; MENOPAUSE; MIDDLE AGED; NAPHTHALIMIDES; NEOPLASM METASTASIS; RECEPTORS, ESTROGEN;

EID: 0029041153     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Hoogstraten, B. Adriamycin (NSC-123 127) in the treatment of advanced breast cancer: studies by the Southwest Oncology Group. Cancer Chemother. Rep., 6: 329–334, 1975.
2. Holmes, F. A., Walters, R. S., Teriault, R. L., Forman, A. D., Newton, L. K., Raber, M. N., Budzar, A. U., Frye, D. K., and Hortobagyi, G. N. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst., 83: 1797–1805, 1991.
3. Talbot, D. C., Smith, I. E., Mansi, J. L., Judson, I., Calvert, A. H., and Ashley, S. E. Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer. J. Clin. Oncol., 9: 2141–2147, 1991.
4. Dawson, N. A., Costanza, M. E., Korzun, A. H., Clamon, G. H., Poliak, M., Vogelzang, N. J., Carey, R. W., and Norton, L. Trimetrexate in untreated and previously treated patient with metastatic breast cancer: a Cancer and Leukemia Group B Study. Med. Pediatr. Oncol., 19: 283–288, 1991.
5. Costanza, M. E., Korzun, A. H., Henderson, I. C., Rice, M. A., Wood, W. C., and Norton, L. Amonafide: an active agent in metastatic breast cancer. Proc. Am. Soc. Clin. Oncol., 9: 31, 1990.
6. Brana, M. F., Castellano, J. M., Roldan, C. M., Santos, A., Vazquez, D., and Jimenez, A. Synthesis and modes of action of a new series of imide derivatives of 3-nitro-l,8-napthalic acid. Cancer Chemother. Pharmacol., 4: 61–66, 1980.
7. Warning, M. J., Gonzalez, A., Jimenez, A., and Vazquez, D. Intercalative binding to DNA of antitumor drugs derived from 3-nitrol-l,8- naphthalic acid. Nucleic Acids Res., 7: 217–230, 1979.
8. Hsiang, Y. U., Jiang, J. B., and Liu, L. F., Topoisomerase II- mediated DNA cleavage by amonafide and its structural analogs. Mol. Pharmacol., 36: 371–376, 1989.
9. Felder, T. B., McLean, M. A., Vestal, M. L., Lu, K., Farquhar, D., Legha, S. S., Shah, R., and Newman, R. A. Pharmacokinetics and metabolism of the antitumor in drug amonafide (NSC-3088457) in humans. Drug Metab. Dispos., 15: 773–778, 1987.
10. Saez, R., Craig, J. B., Kuhn, J. G., Weiss, G. R., Koeller, J., Phillips, J., Havlin, K., Harman, G., Hardy, J., Melink, T. J., Sarosy, G. A., and Von Hoff, D. D. Phase I clinical investigation of amonafide. J. Clin. Oncol., 7: 1351–1358, 1989.
11. Leiby, J. M., Malpeis, L., Staubus, A. E., Kraut, E. H., and Grever, M. R. Amonafide (NSC 308847): a clinical phase I study of two schedules of administration. Proc. Am. Assoc. Cancer Res., 29: 278, 1988.
12. Legha, S. S., Ring, S., Raber, M., Felder, T. B., Newman, R. A., and Krakoff, I. H. Phase I clinical investigation of benzisquinolinedione. Cancer Treat. Rep., 71: 1165–1169, 1987.
13. Scheithauer, W., Dittrich, C., Komek, G., Haider, K., Likesch, W., Gisslinger, H., and Depisch, D. Phase II study of amonafide in advanced breast cancer. Breast Cancer Res. Treat., 20: 63–67, 1991.
14. Ratain, M. J., Rosner, G., Allen, S. L., Costanza, M. E., Van Echo, D. A., Henderson, I. C., and Schilsky, R. L. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. J. Clin. Oncol., 13: 741–747, 1995.
15. Ratain, M. J., Staubus, A. E., Schilsky, R. L., and Malspeis, L. Limited sampling models for amonafide (NSC 308847) pharmacokinetics. Cancer Res., 48: 4127–4130, 1988.
16. Ratain, M. J., Mick, R., Berezin, F., Janisch, L., Schilsky, R. L., Williams, S. F., and Smiddy, J. Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin. Pharmacol. Ther., 50: 573–579, 1991.
17. Ling, V., Gerlach, J. H., Chan, H. S. L., Thomer, P. S., Gariepy, J., Bradley, G., and Georges, E. P-glycoprotein and resistance to anticancer drugs. In: D. E. Bergsagel and T. W. Mak (eds.), Molecular Mechanisms and Their Clinical Applications in Malignancies, pp. 17–34. New York: Academic Press, Inc., 1991.
18. Morrow, C. S., and Cowan, K. H. Multi drug resistance associated with altered topoisomerase II activity; topoisomerase II as a target for rational drug design. J. Natl. Cancer Inst., 82: 638–639, 1990.
19. Frew, A. J., and Kay, A. B. Cell interactions in allergic inflammation. In: P. J. Lachmann, D. K. Peters, F. S. Rosen, and M. J. Walport (eds.), Clinical Aspects of Immunology, Ed. 5, pp. 1105–1118. Oxford: Blackwell Scientific Publications, 1993.
20. Quesada, J. R. Biologic response modifiers in the therapy of metastatic renal cell carcinoma. Semin. Oncol., 15: 396–407, 1988.
21. Mitchell, M. S., Narel, W., Kempf, R. A., Hu, E., Kan-Mitchell, J., Boswell, W. D., Dean, G., and Stevenson, L. Active specific immunotherapy for melanoma. J. Clin. Oncol., 8: 856–869, 1990.
22. Ruckdeschel, J. C., Codish, S. D., Stranahan, A., and McKneally, M. F. Postoperative empyema improves survival in lung cancer. Documentation and analysis of a national experiment. N. Engl. J. Med., 287: 1013–1017, 1992.
23. Ratain, M. J., Mick, R., Berezin, F., Janisch, L., Schilsky, R. L., Vogelzang, N. J., and Lane, L. B. Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res., 53: 2304–2308, 1993.